These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 32770586)

  • 1. Tuberculosis drug safety and pharmacovigilance in health system of Kosova: A cross-sectional analysis.
    Krasniqi S; Neziri B; Jakupi A; Shurdhaj I; Daci A; Jupolli-Krasniqi N; Pira M
    Pharmacoepidemiol Drug Saf; 2020 Sep; 29(9):1037-1045. PubMed ID: 32770586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 'Have we missed reporting adverse drug reactions under Revised National TB Control Programme?' - A mixed method study in Bengaluru, India.
    Krishnappa L; Gadicherla S; Chidambaram P; Anuradha HV; Somanna SN; Naik PR; Das A; Narasimhaiah S; Nagaraja SB
    Indian J Tuberc; 2020 Jan; 67(1):20-28. PubMed ID: 32192612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. "Side effects--part of the package": a mixed methods approach to study adverse events among patients being programmatically treated for DR-TB in Gujarat, India.
    Jakasania A; Shringarpure K; Kapadia D; Sharma R; Mehta K; Prajapati A; Kathirvel S
    BMC Infect Dis; 2020 Dec; 20(1):918. PubMed ID: 33267826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of family, society and national policy support on treatment adherence among newly diagnosed tuberculosis patients: a cross-sectional study.
    Chen X; Du L; Wu R; Xu J; Ji H; Zhang Y; Zhu X; Zhou L
    BMC Infect Dis; 2020 Aug; 20(1):623. PubMed ID: 32831050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidemiological and behavioural correlates of drug-resistant tuberculosis in a Tertiary Care Centre, Delhi, India.
    Dzeyie KA; Basu S; Dikid T; Bhatnagar AK; Chauhan LS; Narain JP
    Indian J Tuberc; 2019 Jul; 66(3):331-336. PubMed ID: 31439176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of adverse events on health-related quality of life among patients receiving treatment for drug-resistant tuberculosis in Johannesburg, South Africa.
    Sineke T; Evans D; Schnippel K; van Aswegen H; Berhanu R; Musakwa N; Lönnmark E; Long L; Rosen S
    Health Qual Life Outcomes; 2019 May; 17(1):94. PubMed ID: 31151398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence of adverse reactions caused by first-line anti-tuberculosis drugs and treatment outcome of pulmonary tuberculosis patients in Morocco.
    El Hamdouni M; Ahid S; Bourkadi JE; Benamor J; Hassar M; Cherrah Y
    Infection; 2020 Feb; 48(1):43-50. PubMed ID: 31165445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prevalence and factors associated for anti-tuberculosis treatment non-adherence among pulmonary tuberculosis patients in public health care facilities in South Ethiopia: a cross-sectional study.
    Woimo TT; Yimer WK; Bati T; Gesesew HA
    BMC Public Health; 2017 Mar; 17(1):269. PubMed ID: 28320351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tuberculosis case management and treatment outcome: assessment of the effectiveness of Public-Private Mix of tuberculosis programme in Kaduna State, Nigeria.
    Gidado M; Ejembi CL
    Ann Afr Med; 2009; 8(1):25-31. PubMed ID: 19763003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Noncompliance of treatment among tuberculosis patients in intensive phase at Kalutara District of Sri Lanka.
    Ranawaka N; Nandasena S; De Alwis S
    Indian J Tuberc; 2021 Apr; 68(2):266-271. PubMed ID: 33845963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Severe adverse events during second-line tuberculosis treatment in the context of high HIV Co-infection in South Africa: a retrospective cohort study.
    Schnippel K; Berhanu RH; Black A; Firnhaber C; Maitisa N; Evans D; Sinanovic E
    BMC Infect Dis; 2016 Oct; 16(1):593. PubMed ID: 27769174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacovigilance monitoring and treatment adherence in patients on anti-tubercular drugs.
    Matreja PS; Garg R; Maqusood M
    Indian J Tuberc; 2023 Oct; 70(4):409-415. PubMed ID: 37968046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing the prevalence and effect of adverse drug reactions among patients receiving first line anti-tubercular medicines in the Tamale Teaching Hospital, Ghana.
    Amalba A; Bugri AA
    Pan Afr Med J; 2021; 38():191. PubMed ID: 33995797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differences in VigiBase® reporting of aminoglycoside and capreomycin-suspected ototoxicity during tuberculosis treatment.
    Sagwa EL; Souverein PC; Ribeiro I; Leufkens HG; Mantel-Teeuwisse AK
    Pharmacoepidemiol Drug Saf; 2017 Jan; 26(1):1-8. PubMed ID: 27868278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tuberculosis in Poland in 2017.
    Korzeniewska- Koseła M
    Przegl Epidemiol; 2019; 73(2):211-226. PubMed ID: 31385679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integration of drug safety monitoring in tuberculosis treatment programmes: country experiences.
    Tiemersma E; van den Hof S; Dravniece G; Wares F; Molla Y; Permata Y; Lukitosari E; Quelapio M; Aung ST; Aung KM; Thuy HT; Hoa VD; Sulaimanova M; Sagyndikova S; Makhmudova M; Soliev A; Kimerling M
    Eur Respir Rev; 2019 Sep; 28(153):. PubMed ID: 31604816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of medicines-Pharmacists' knowledge, practice, and attitudes toward pharmacovigilance and adverse drug reactions reporting process.
    Kopciuch D; Zaprutko T; Paczkowska A; Ratajczak P; Zielińska-Tomczak Ł; Kus K; Nowakowska E
    Pharmacoepidemiol Drug Saf; 2019 Dec; 28(12):1543-1551. PubMed ID: 31148344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment Adherence of Tuberculosis Patients Attending Two Reference Units in Equatorial Guinea.
    Fagundez G; Perez-Freixo H; Eyene J; Momo JC; Biyé L; Esono T; Ondó Mba Ayecab M; Benito A; Aparicio P; Herrador Z
    PLoS One; 2016; 11(9):e0161995. PubMed ID: 27622461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Putting in harm to cure: Drug related adverse events do not affect outcome of patients receiving treatment for multidrug-resistant Tuberculosis. Experience from a tertiary hospital in Italy.
    Gualano G; Mencarini P; Musso M; Mosti S; Santangelo L; Murachelli S; Cannas A; Di Caro A; Navarra A; Goletti D; Girardi E; Palmieri F
    PLoS One; 2019; 14(2):e0212948. PubMed ID: 30817779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of renal function-based anti-tuberculosis drug dosage adjustment on efficacy and safety outcomes in pulmonary tuberculosis complicated with chronic kidney disease.
    Saito N; Yoshii Y; Kaneko Y; Nakashima A; Horikiri T; Saito Z; Watanabe S; Kinoshita A; Saito K; Kuwano K
    BMC Infect Dis; 2019 May; 19(1):374. PubMed ID: 31046706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.